2020 | Aculabs Inc

Letter from the Director: Reticulocyte Comprehensive Panel assists in assessing red blood cell production

Published December 2020 as part of Aculabs’ LabTalk quarterly newsletter. Aculabs will be offering a Reticulocyte Comprehensive Panel – the panel can provide comprehensive information needed by physicians to assess the rate of red cell production and hemoglobinization. Reticulocyte count (RET #, %) indicates the quantity of circulating reticulocytes. The Immature Reticulocyte Fraction (IRF) indicates

By Dylan Smith|2021-10-29T15:31:42-04:00December 29th, 2020|Categories: Quarterly Letter|Comments Off

Letter from the Director: Understanding Antibody Testing Provided by Aculabs

Antibodies are proteins produced by the immune system in response to infection, often within the first week of post-symptoms onset. There are several forms of antibodies: IgG, IgM, IgA, as well as other forms. However, not all antibodies are created equal; some are considered to be binding antibody and some are neutralizing. A neutralizing

By Dylan Smith|2021-01-26T10:25:55-05:00December 29th, 2020|Categories: Quarterly Letter|Comments Off

Official Aculabs Response to BinaxNOW Pilot Program

Aculabs would like to take this time to update all client facilities regarding a number of key issues that our industry faces in the coming week(s). Please take a moment to read the following measures. 2 Week Testing Pilot and BinaxNOW Test Cards November 20th, 2020 - The State of New Jersey

By Dylan Smith|2021-10-29T15:25:03-04:00November 20th, 2020|Categories: News|0 Comments

Improving the Accuracy of Collection Info & Turnaround Times

In reviewing our turnaround times for our various COVID-19 testing options, it recently came to our team's attention that some client facilities are not inputting in the proper Collection Date and Time. The collection date and time are taken from the COLLECTION DATE and COLLECTION TIME fields from the web portal when placing an order.

By Dylan Smith|2021-10-29T15:28:09-04:00October 8th, 2020|Categories: News|0 Comments

CMS Updates Rules on LTC Testing Requirements for COVID-19

10/09/20 NOTICE: PLEASE READ OUR MEMO REGARDING OUR EMPLOYEE SAFETY PROTOCOLS August 26, 2020 - CMS has issued CMS-3401-IFC, "Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency related to Long-Term Care (LTC) Facility Testing Requirements and Revised COVID-19 Focused Survey Tool", expanding standards that LTCs must follow to prevent

By Dylan Smith|2021-10-29T15:26:42-04:00August 27th, 2020|Categories: News|0 Comments

Aculabs Begins Implementing SARS-CoV-2 Testing for COVID-19

April 7, 2020 - Aculabs will immediately begin performing COVID-19 screenings via the BioGX SARS-CoV-2 Reagents for BD MAX™ System, a real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2. The ability to perform screenings will allow for result reporting within 24 hours, vital to the high-risk populations Aculabs services as

By Dylan Smith|2020-07-09T09:37:14-04:00April 7th, 2020|Categories: News|0 Comments

SARS-CoV-2 Testing Now Available at New Jersey Public Health and Environmental Laboratories

4/7/20: Aculabs now offers SARS-CoV-2 testing for COVID-19 - Read More The New Jersey Department of Health has announced, starting on February 28, 2020, that the CDC SARS-CoV-2 real-time RT-PCR test will now be available at New Jersey Public Health and Environmental Laboratories. For the convenience of client facilities, Aculabs will participate in shipping the

By Dylan Smith|2020-04-14T12:10:54-04:00March 3rd, 2020|Categories: News|0 Comments